Advanced kidney cancer Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user walking in a field with her son.
Potential OPDIVO® (nivolumab) user walking in a field with her son.

Clinical trial results
for advanced
kidney cancer

For certain adults with previously untreated kidney cancer that has spread (advanced renal cell carcinoma)

Actor portrayals.
OPDIVO + CABOMETYX is not approved
for people younger than 18 years of age.

An FDA-approved combination of immunotherapy and targeted therapy that helped people live longer without their cancer spreading, growing, or getting worse compared to SUTENT

About the clinical trial

In a clinical trial of 651 people with previously untreated advanced kidney cancer that had spread, 323 people were given OPDIVO + CABOMETYX and 328 people were given SUTENT® (sunitinib malate), a standard treatment.

People given OPDIVO + CABOMETYX lived longer without their cancer spreading, growing, or getting worse compared to SUTENT

At 17 months, half the people given OPDIVO® + CABOMETYX® were alive.
OPDIVO + CABOMETYX

Half the people went without their cancer spreading, growing, or getting worse

At 8 months, half the people given SUTENT® were alive.
SUTENT

Half the people went without their cancer spreading, growing, or getting worse

People given OPDIVO + CABOMETYX had a 49% lower risk of their cancer spreading, growing, or getting worse than those given SUTENT.

More people given OPDIVO + CABOMETYX saw their tumors
shrink or disappear completely compared to SUTENT

OPDIVO + CABOMETYX

SUTENT

Tumors disappeared completely
(complete response)

8% saw tumors disappear completely in response to OPDIVO® + CABOMETYX® compared to 5% in response to SUTENT®.

Tumors shrank
(partial response)

48% saw tumors shrink in response to OPDIVO® + CABOMETYX® compared to 23% in response to SUTENT® for advanced RCC.

Tumors shrank or disappeared completely (overall response)

56% given OPDIVO® + CABOMETYX® saw an overall response to treatment compared to 27% given SUTENT®.

In a clinical trial, people given OPDIVO + CABOMETYX had a 40% lower risk of dying than those given SUTENT.
 

Words to know

Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.

Partial response is when a tumor reacts to treatment and shrinks.

Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.

OPDIVO + CABOMETYX will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread

OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.